Imugene Limited | Businesses

Imugene Limited

Phone: +61 3 9824 5254

Add/Update information

Reviews

Tags

• Businesses
• Science, technology & engineering
• Biotechnology company

20.01.2022 Very encouraging work from our friends City of Hope who have combined two potent immunotherapies, an oncolytic virus and chimeric antigen receptor (CAR) T cell therapy to target and eradicate solid tumors otherwise difficult to treat with CAR T therapy. View their 4-minute video: http://ow.ly/G7rH50BnSq4 #immunotherapies #oncolyticvirus #endcancer #cancerresearch

20.01.2022 Imugene boosts balance sheet with $5.7 million option underwriting agreement. The agreement with Bell Potter further strengthens the company’s financial position building on the existing cash balance of $30.1 million as of June 30, 2020. https://www.proactiveinvestors.com.au//imugene-boosts-bala... #Cancer #immunotherapy #endcancer #asx

19.01.2022 Imugene (ASX:IMU) recieves approval for phase one trial for lung cancer. Approval for the FDA IND is scheduled for the fourth quarter of 2020, after which the company will proceed with site activation and patient recruitment. Hackensack University Medical Centre in New Jersey is the first hospital in the U.S. to receive WIRB ethics approval.... http://ow.ly/oojQ30r8cq0

18.01.2022 Imugene's OV SAB Chair Prof Yuman Fong's lab has designed an oncolytic virus that delivers CD19 to tumor cells, which can then be targeted with CD19-specific CAR T cells. Very exciting news for cancer therapy. #endcancer #research #cityofhope #celltherapy #immunotherapy

17.01.2022 Imugene has a high likelihood of clinical success: Roth Capital Partners #immunotherapies #immunooncology #biotechnologyindustry

12.01.2022 "We are delighted to have secured this funding commitment," Imugene CEO Leslie Chong said. "With our existing cash reserves, this ensures we are well-positioned to deliver on our commercial and clinical milestones," she added. https://themarketherald.com.au/imugene-asximu-signs-5-7m-o/... #Cancer #asx #immunotherapy #endcancer #oncology

12.01.2022 Imugene has a high likelihood of clinical success: Roth Capital Partners #immunotherapies #immunooncology #biotechnologyindustry

09.01.2022 This article features our CEO Leslie Chong discussing her close friend's battle with Stage 3 Triple Negative Breast Cancer (TNBC). Leslie commented: "TNBC is harder to treat because it does not express genes for oestrogen, progesterone and HER2, which makes it difficult to find where the cancer is coming from." Read time: 2 min... http://ow.ly/Qjcs50BPvbZ #BreastCancer #EndCancer #Immunotherapy #Oncology #BioTech

07.01.2022 StockTalk is a Stockhead video series featuring a roundtable of experts discussing a new investment topic each week. In this edition, host Dr Nigel Finch discusses ASX health and biotechnology companies focused on fighting cancer. Featuring our CEO & MD, Leslie Chong. https://stockhead.com.au//asx-small-caps-leading-the-figh/... #immunotherapies #immunooncology #pharma #ASX #biotechnology #bioetch #lifescience #medtech

07.01.2022 ASX Announcement ! Imugene Growth Factor Immunotherapy Combination Patent Granted in United States > Core US patent granted in world’s largest pharmaceutical market;... > Patent provides method of composition and method of use protection to 2035. Imugene’s M.D. & CEO, Ms Leslie Chong said, Attaining the key US patent is an important milestone. This adds extra value to Imugene’s portfolio of B-cell immunotherapies and this will protect them in the world’s largest pharmaceutical market until 2035. Read today’s news https://www.imugene.com/announcements #immunotherapies #immunooncology #ASX #endcancer

05.01.2022 Imugene Limited (ASX:IMU) a clinical stage immuno-oncology company today announced the appointment of Dr Rita Laeufle, MD PhD, as Chief Medical Officer (CMO) and a member of the Company's executive leadership team. Dr Laeufle will lead the Company’s global clinical development, regulatory and medical monitoring activities, replacing Dr Mark Marino who is stepping down from his position. https://www.imugene.com/announcements... ASX: IMU

03.01.2022 Imugene's Leslie Chong says Roth Capital Partners' report is 'great accomplishment' #immunotherapies #immunooncology

03.01.2022 Listen to ASX-listed Imugene MD, Leslie Chong, talk to Matt Birney on the 6PR Bulls N’ Bears report about Imugene’s suite of biotechnology products that are leading the fight against cancer. #immunotherapies #lifescience #bioetch #immunooncology

02.01.2022 We are very proud to congratulate our Scientific Advisory Board member, Professor Pravin Kaumaya, inventor of PD1-Vaxx who has been nominated for OSU Innovator of the Year. This short video produced by the OSU Research Office is beautifully made and captures the excitement of combination treatments as the future of immuno-oncology. PD1-Vaxx is now being tested in lung cancer patients and could very well be leading a paradigm shift in cancer treatment.... #oncologyresearch #cancerresearch #healthcare #immunotherapy #immunooncology #lungcancer #endcancer #ASX #OSU #Imugene #PD1VAXX #immunotherapies ASX: IMU https://www.youtube.com/watch?v=GcrcEWJr9Ms

02.01.2022 ! NEW Analyst Coverage | ROTH Capital Partners Healthcare: Biotechnology Imugene Limited | IMU.AX - AUD0.05 - ASX | Buy... IMU.AX: Engineered Oncolytic Viruses and B Cell Immunotherapies to Fight Cancer VIEW https://www.imugene.com/analyst-coverage #immunotherapies #immunooncology #ASX #endcancer #biotechnology #biotech #biotechnologyindustry #pharma

01.01.2022 Imugene Attains First US Ethics Approval from WIRB to Begin PD1-Vaxx’s Phase I trial Via Kalkine Media http://ow.ly/Xajq50BkpxV #cancer #immunotherapy #asx #endcancer #oncology